COSCIENS Biopharma Inc. Proceeds From Issue Of Ordinary Shares
COSCIENS Biopharma Inc. (CSCIF) reported Proceeds From Issue Of Ordinary Shares of $34.20 million for the 12-month period ending 2021-12-31, per its 20-F filed 2022-03-29.
Discontinued › Cash Flow › Financing Activities
ifrs-full:ProceedsFromIssueOfOrdinaryShares · last filed 2024-02-15
- COSCIENS Biopharma Inc. proceeds from issue of ordinary shares for the quarter ending 2021-12-31 was $0.00.
- COSCIENS Biopharma Inc. proceeds from issue of ordinary shares for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- COSCIENS Biopharma Inc. proceeds from issue of ordinary shares for the quarter ending 2021-06-30 was $0.00.
- COSCIENS Biopharma Inc. proceeds from issue of ordinary shares for the quarter ending 2021-03-31 was $34.20M, a 660.00% increase year-over-year.
| Period end | Proceeds From Issue Of Ordinary Shares 0 month | Proceeds From Issue Of Ordinary Shares 3 month | Proceeds From Issue Of Ordinary Shares 6 month | Proceeds From Issue Of Ordinary Shares 9 month | Proceeds From Issue Of Ordinary Shares 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 derived: sum of 3 quarters · filed 2022-11-03 | $34.20M 20-F · filed 2022-03-29 | |
| 2021-09-30 | $0.00 derived: 6-K 9 month − 6-K/A 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $34.20M 6-K · filed 2022-11-03 | $34.20M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 6-K/A 6 month − 6-K 3 month · filed 2022-08-04 | $34.20M 6-K/A · filed 2022-08-04 | $34.20M derived: sum of 3 quarters · filed 2022-08-04 | $53.20M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $34.20M 6-K · filed 2022-05-11 | $34.20M derived: sum of 2 quarters · filed 2022-05-11 | $53.20M derived: sum of 3 quarters · filed 2022-05-11 | $53.20M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $0.00 derived: 40-F/A 12 month − 6-K 9 month · filed 2021-03-29 | $19.00M derived: sum of 2 quarters · filed 2021-03-29 | $19.00M derived: sum of 3 quarters · filed 2021-03-29 | $23.50M 40-F/A · filed 2021-03-29 | |
| 2020-09-30 | $19.00M 6-K · filed 2020-11-05 | $19.00M derived: sum of 2 quarters · filed 2020-11-05 | $23.50M 6-K · filed 2020-11-05 | $23.50M derived: sum of 4 quarters · filed 2021-03-29 | |
| 2020-07-07 | $12.00M 20-F/A · filed 2024-02-15 | ||||
| 2020-06-30 | $0.00 derived: 6-K 6 month − 6-K/A 3 month · filed 2020-08-06 | $4.50M 6-K · filed 2020-08-06 | $4.50M derived: sum of 3 quarters · filed 2021-03-29 | $9.49M derived: sum of 4 quarters · filed 2021-03-29 | |
| 2020-03-31 | $4.50M 6-K/A · filed 2020-05-11 | $4.50M derived: sum of 2 quarters · filed 2021-03-29 | $9.49M derived: sum of 3 quarters · filed 2021-03-29 | $9.80M derived: sum of 4 quarters · filed 2021-03-29 | |
| 2019-12-31 | $0.00 derived: 40-F/A 12 month − 6-K 9 month · filed 2021-03-29 | $4.99M derived: sum of 2 quarters · filed 2021-03-29 | $5.30M derived: sum of 3 quarters · filed 2021-03-29 | $4.99M 40-F/A · filed 2021-03-29 | |
| 2019-09-30 | $4.99M 6-K · filed 2020-11-05 | $5.30M derived: sum of 2 quarters · filed 2020-11-05 | $4.99M 6-K · filed 2020-11-05 | ||
| 2019-09-20 | $4.99M 40-F/A · filed 2021-03-29 | ||||
| 2019-06-30 | $314.00K 6-K · filed 2020-08-06 | $314.00K 6-K · filed 2020-08-06 | |||
| 2017-12-31 | $8.04M 20-F · filed 2020-03-31 |